CliffBio
small molecule

ABILIFY ASIMTUFII

ARIPIPRAZOLE

Loss of exclusivityApril 2033latest FDA-listed patent expiry
CompanyOtsuka Pharmaceutical →View the full company profile on CliffBio

Drug detail

Brand nameABILIFY ASIMTUFII
Active ingredientARIPIPRAZOLE
Strength720MG/2.4ML (300MG/ML)
Dosage formSUSPENSION, EXTENDED RELEASE
RouteINTRAMUSCULAR
ModalitySmall molecule
FDA approvalApril 2023
Marketing statusRX

Listed patents

PatentExpiresType
12016927April 2033product
11638757April 2033product
11097007April 2033product
10517951April 2033product

More from Otsuka Pharmaceutical

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ABILIFY ASIMTUFII patent cliff — loss of exclusivity April 2033 | CliffBio